https://www.businesswire.com/news/home/20181028005002/en/

BOSTON--(BUSINESS WIRE)--Oct 28, 2018--On Monday, October 29, Senior Director of Corporate Development at Immunomic Therapeutics Inc. Sia Anagnostou will speak at the Precision Lung Cancer World R&D Summit in Boston. Anagnostou’s presentation, titled “UNITE Technology as Nucleic Acid & Cell Based Immunotherapy: TERT - LAMP Case Study,” will highlight Immunomic’s investigational UNiversal Intracellular Targeted Expression (UNITE) platform and its application in immuno-oncology. Immunomic’s technology platform has the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory, a method that could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer. The investigational UNITE technology is currently being applied as a cancer immunotherapy in a Phase II clinical trial targeting glioblastoma multiforme (GBM). Anagnostou’s presentation will explore the broader potential of UNITE through discussion of the LAMP-based immunotherapy technology, AST-VAC2 (VAC2). VAC2 is an allogeneic cancer immunotherapy being developed by Asterias Biotherapeutics, Inc. in collaboration with Cancer Research UK and is currently in a Phase 1 clinical trial for treatment of non-small cell lung cancer.

Who: Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc.